RU2540337C2 - N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ - Google Patents

N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ Download PDF

Info

Publication number
RU2540337C2
RU2540337C2 RU2013116924/04A RU2013116924A RU2540337C2 RU 2540337 C2 RU2540337 C2 RU 2540337C2 RU 2013116924/04 A RU2013116924/04 A RU 2013116924/04A RU 2013116924 A RU2013116924 A RU 2013116924A RU 2540337 C2 RU2540337 C2 RU 2540337C2
Authority
RU
Russia
Prior art keywords
mmol
tert
reaction mixture
methyl
carboxylic acid
Prior art date
Application number
RU2013116924/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2013116924A (ru
Inventor
Скотт Уильям Бэгли
Роберт Ли Доу
Дэвид Эндрю Гриффит
Аарон Кристофер СМИТ
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2013116924A publication Critical patent/RU2013116924A/ru
Application granted granted Critical
Publication of RU2540337C2 publication Critical patent/RU2540337C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2013116924/04A 2010-10-29 2011-10-18 N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ RU2540337C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40812710P 2010-10-29 2010-10-29
US61/408,127 2010-10-29
US201161531744P 2011-09-07 2011-09-07
US61/531,744 2011-09-07
PCT/IB2011/054643 WO2012056372A1 (en) 2010-10-29 2011-10-18 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS

Publications (2)

Publication Number Publication Date
RU2013116924A RU2013116924A (ru) 2014-12-10
RU2540337C2 true RU2540337C2 (ru) 2015-02-10

Family

ID=44993633

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013116924/04A RU2540337C2 (ru) 2010-10-29 2011-10-18 N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ

Country Status (26)

Country Link
US (3) US8859773B2 (enExample)
EP (2) EP2952514A1 (enExample)
JP (2) JP5647356B2 (enExample)
KR (2) KR101529404B1 (enExample)
CN (2) CN103189377B (enExample)
AR (1) AR083578A1 (enExample)
AU (1) AU2011322117B2 (enExample)
BR (1) BR112013010310A2 (enExample)
CA (1) CA2815169C (enExample)
CY (1) CY1116405T1 (enExample)
DK (1) DK2632925T3 (enExample)
ES (1) ES2546465T3 (enExample)
HK (1) HK1209733A1 (enExample)
HU (1) HUE025078T2 (enExample)
IL (1) IL225779A0 (enExample)
MX (1) MX2013004733A (enExample)
NZ (1) NZ609527A (enExample)
PL (1) PL2632925T3 (enExample)
PT (1) PT2632925E (enExample)
RU (1) RU2540337C2 (enExample)
SG (1) SG189883A1 (enExample)
SI (1) SI2632925T1 (enExample)
TW (3) TW201531472A (enExample)
UY (1) UY33694A (enExample)
WO (1) WO2012056372A1 (enExample)
ZA (1) ZA201303882B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11325909B2 (en) 2017-11-21 2022-05-10 Pfizer Inc. Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypryridin-2-YL)benzoic acid

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025078T2 (en) * 2010-10-29 2016-01-28 Pfizer N1 / N2-lactam-acetyl-CoA carboxylase inhibitors
JP6321042B2 (ja) 2013-02-06 2018-05-09 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規なハロゲン置換された化合物
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103214327A (zh) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
CN104230922B (zh) 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
KR20160104065A (ko) 2014-01-03 2016-09-02 바이엘 애니멀 헬스 게엠베하 농약으로서의 신규 피라졸릴헤테로아릴아미드
CN104844509A (zh) * 2014-02-14 2015-08-19 河南工业大学 一种条件温和无金属参与的胺基喹啉衍生物的制备方法
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
CN104610143A (zh) * 2015-02-12 2015-05-13 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
AU2016231174B2 (en) 2015-03-10 2020-09-10 Bayer Animal Health Gmbh Pyrazolyl-derivatives as pest control agents
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
JP7282039B2 (ja) * 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Mk2阻害剤、その合成、およびそれに至るまでの中間体
WO2018166493A1 (zh) 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Mk2阻害剤として有用なヘテロアリール化合物
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN109824669A (zh) * 2018-12-21 2019-05-31 西南大学 哌啶螺环酒石酸类化合物制备及应用
EP4149917B1 (en) * 2020-05-12 2025-07-30 Merck Sharp & Dohme LLC Factor xi activation inhibitors
EP4154880A4 (en) 2020-05-21 2024-06-05 Shionogi & Co., Ltd Pharmaceutical for treating fatty liver diseases
TW202246282A (zh) 2021-02-01 2022-12-01 美商西建公司 Mk2抑制劑、其合成及其中間體
EP4358948A4 (en) * 2021-06-25 2025-05-14 Cedilla Therapeutics, Inc. TEAD INHIBITORS AND USES THEREOF
CN120019059A (zh) * 2022-07-29 2025-05-16 辉瑞公司 新型acc抑制剂
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor
TW202602453A (zh) * 2024-03-14 2026-01-16 智擎生技製藥股份有限公司 Mta協同性的prmt5抑制劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200900613A1 (ru) * 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002100A (en) 1932-06-27 1935-05-21 Smith Sheffield Shock absorber
JPS4925673B1 (enExample) * 1970-05-22 1974-07-02
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
GEP20053710B (en) 2001-02-28 2005-12-26 Merck & Co Inc Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
BR0212123A (pt) 2001-08-24 2004-07-20 Upjohn Co 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
WO2003072578A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
EP1753748B1 (en) 2004-05-12 2009-07-29 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
KR20080036041A (ko) 2005-07-19 2008-04-24 머크 앤드 캄파니 인코포레이티드 아세틸 조효소 카복실라제(acc) 억제제로서의스피로크로마논 유도체
WO2007013691A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EP2463283B1 (en) 2006-04-20 2014-06-11 Pfizer Products Inc. Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
CA2683695C (en) 2007-04-12 2013-06-18 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
CA2724603A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8524730B2 (en) 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
WO2010008521A1 (en) * 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
MX2011002166A (es) 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
JP2012526096A (ja) 2009-05-08 2012-10-25 ファイザー・インク Gpr119調節因子
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Gpr119調節因子
KR20120061063A (ko) 2009-06-05 2012-06-12 화이자 인코포레이티드 Gpr 119 조절제로서의 l-(피페리딘-4-일)-피라졸 유도체
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
JP2013510191A (ja) * 2009-11-10 2013-03-21 ファイザー・インク N−2ピラゾロスピロケトンアセチル−CoAカルボキシラーゼ阻害薬
PT2499139E (pt) * 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
HUE025078T2 (en) * 2010-10-29 2016-01-28 Pfizer N1 / N2-lactam-acetyl-CoA carboxylase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200900613A1 (ru) * 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11325909B2 (en) 2017-11-21 2022-05-10 Pfizer Inc. Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypryridin-2-YL)benzoic acid

Also Published As

Publication number Publication date
JP2013542218A (ja) 2013-11-21
TWI441823B (zh) 2014-06-21
TW201302751A (zh) 2013-01-16
HUE025078T2 (en) 2016-01-28
US9181252B2 (en) 2015-11-10
US20150025098A1 (en) 2015-01-22
AR083578A1 (es) 2013-03-06
KR101529404B1 (ko) 2015-06-26
US8993586B2 (en) 2015-03-31
US20120108619A1 (en) 2012-05-03
TW201531472A (zh) 2015-08-16
CA2815169A1 (en) 2012-05-03
US20150152109A1 (en) 2015-06-04
TW201418256A (zh) 2014-05-16
HK1186724A1 (en) 2014-03-21
ZA201303882B (en) 2014-02-26
US8859773B2 (en) 2014-10-14
PT2632925E (pt) 2015-09-01
KR20140014078A (ko) 2014-02-05
NZ609527A (en) 2014-03-28
EP2952514A1 (en) 2015-12-09
JP2015057416A (ja) 2015-03-26
EP2632925B1 (en) 2015-05-27
EP2632925A1 (en) 2013-09-04
CY1116405T1 (el) 2017-02-08
PL2632925T3 (pl) 2015-10-30
WO2012056372A1 (en) 2012-05-03
CN104774205A (zh) 2015-07-15
CN103189377B (zh) 2015-02-25
ES2546465T3 (es) 2015-09-23
IL225779A0 (en) 2013-06-27
AU2011322117A1 (en) 2013-05-02
SI2632925T1 (sl) 2015-07-31
CA2815169C (en) 2015-10-06
AU2011322117B2 (en) 2015-01-22
RU2013116924A (ru) 2014-12-10
UY33694A (es) 2012-05-31
MX2013004733A (es) 2013-07-02
SG189883A1 (en) 2013-06-28
JP5647356B2 (ja) 2014-12-24
BR112013010310A2 (pt) 2016-11-29
HK1209733A1 (en) 2016-04-08
TWI507406B (zh) 2015-11-11
KR20150006899A (ko) 2015-01-19
DK2632925T3 (en) 2015-06-29
CN103189377A (zh) 2013-07-03

Similar Documents

Publication Publication Date Title
US8993586B2 (en) N1/N2-lactam acetyl-CoA carboxylase inhibitors
US8802688B2 (en) Substituted acetyl-coa carboxylase inhibitors
OA16631A (en) Pyrazolospiroketone derivatives for use as ACETYL-COA Carboxylase inhibitors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161019